Literature DB >> 15010378

Clinical use of intensity-modulated radiotherapy: part I.

M T Guerrero Urbano1, C M Nutting.   

Abstract

Intensity-modulated radiotherapy (IMRT) is a novel conformal radiotherapy technique which is gaining increasing clinical use worldwide. This article aims to summarize the published data pertaining to clinical indications of this therapy for head and neck, central nervous system, and lung tumours. The main indications in head and neck cancer are parotid gland sparing and dose escalation to tumours close to organs at risk. For central nervous system tumours, IMRT has been used to reduce normal tissue radiation by more conformal dose distributions. To date, the majority of reports concern patients treated in the context of clinical trials, and for most tumour types longer term follow up of treated patients will be required to confirm the clinical benefits of IMRT.

Entities:  

Mesh:

Year:  2004        PMID: 15010378     DOI: 10.1259/bjr/84246820

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  12 in total

Review 1.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

Review 2.  Nanotechnology in radiation oncology.

Authors:  Andrew Z Wang; Joel E Tepper
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 3.  Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.

Authors:  Christopher M Hartshorn; Michelle S Bradbury; Gregory M Lanza; Andre E Nel; Jianghong Rao; Andrew Z Wang; Ulrich B Wiesner; Lily Yang; Piotr Grodzinski
Journal:  ACS Nano       Date:  2017-12-22       Impact factor: 15.881

4.  Successful treatment of quintuple primary cancer, including esophageal cancer: A case report.

Authors:  Yasunori Otowa; Tetsu Nakamura; Gosuke Takiguchi; Naoki Urakawa; Ryo Ishida; Tatsuya Imanishi; Satoshi Suzuki; Kenichi Tanaka; Daisuke Kuroda; Yoshihiro Kakeji
Journal:  Oncol Lett       Date:  2015-03-27       Impact factor: 2.967

5.  Clinical outcome in dogs with nasal tumors treated with intensity-modulated radiation therapy.

Authors:  David W Hunley; G Neal Mauldin; Keijiro Shiomitsu; Glenna E Mauldin
Journal:  Can Vet J       Date:  2010-03       Impact factor: 1.008

6.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

Review 7.  Radiation therapy for children: evolving technologies in the era of ALARA.

Authors:  Larry E Kun; Chris Beltran
Journal:  Pediatr Radiol       Date:  2008-12-16

8.  Dosimetric Effect of Jaw Tracking in Volumetric-Modulated Arc Therapy.

Authors:  Sangutid Thongsawad; Chirasak Khamfongkhruea; Chirapha Tannanonta
Journal:  J Med Phys       Date:  2018 Jan-Mar

9.  Volumetric intensity-modulated arc therapy vs conventional intensity-modulated radiation therapy in nasopharyngeal carcinoma: a dosimetric study.

Authors:  Peter White; Kit Chi Chan; Ka Wai Cheng; Ka Yiu Chan; Ming Chun Chau
Journal:  J Radiat Res       Date:  2012-11-27       Impact factor: 2.724

10.  SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocol.

Authors:  Robert Olson; Roel Schlijper; Nick Chng; Quinn Matthews; Marco Arimare; Lindsay Mathews; Fred Hsu; Tanya Berrang; Alexander Louie; Benjamin Mou; Boris Valev; Joanna Laba; David Palma; Devin Schellenberg; Shilo Lefresne
Journal:  BMC Cancer       Date:  2019-10-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.